^
    Apply
    A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors (NCT05538572)
    Phase 1
    Prelude Therapeutics
    Active, not recruiting
    Last update posted :
    01/17/2024
    Initiation :
    12/27/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B
    |
    KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type
    |
    PRT3645